Lerong Li

3.4k total citations · 2 hit papers
21 papers, 1.4k citations indexed

About

Lerong Li is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Lerong Li has authored 21 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 7 papers in Molecular Biology and 6 papers in Cancer Research. Recurrent topics in Lerong Li's work include Lung Cancer Research Studies (6 papers), Lung Cancer Treatments and Mutations (5 papers) and Cancer Genomics and Diagnostics (4 papers). Lerong Li is often cited by papers focused on Lung Cancer Research Studies (6 papers), Lung Cancer Treatments and Mutations (5 papers) and Cancer Genomics and Diagnostics (4 papers). Lerong Li collaborates with scholars based in United States, China and United Kingdom. Lerong Li's co-authors include Jing Wang, John V. Heymach, Lauren A. Byers, Triparna Sen, Lixia Diao, Bonnie S. Glisson, Don L. Gibbons, You-Hong Fan, Julien Sage and Sandra Cristea and has published in prestigious journals such as Nature, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Lerong Li

20 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer

2019 616 citations Triparna Sen, B. Leticia Rodriguez et al. Cancer Discovery profile →
Interim analyses of a first-in-human phase 1/2 mRNA trial for propionic acidaemia

2024 55 citations Dwight D. Koeberl, Andreas Schulze et al. Nature profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lerong Li United States	14	827	699	386	232	215	21	1.4k
Kyle K. Payne United States	22	699 0.8×	544 0.8×	765 2.0×	109 0.5×	120 0.6×	42	1.5k
Falguni Parikh India	13	747 0.9×	474 0.7×	425 1.1×	75 0.3×	155 0.7×	50	1.3k
Heather Tillman United States	20	297 0.4×	580 0.8×	419 1.1×	115 0.5×	176 0.8×	37	1.2k
Jean-Michel Vernes United States	12	552 0.7×	613 0.9×	462 1.2×	77 0.3×	89 0.4×	15	1.3k
Sumita Trivedi United States	17	843 1.0×	417 0.6×	583 1.5×	131 0.6×	289 1.3×	33	1.5k
Andrew D. Simmons United States	19	652 0.8×	583 0.8×	289 0.7×	48 0.2×	325 1.5×	60	1.2k
Alice Guyard France	9	497 0.6×	336 0.5×	243 0.6×	67 0.3×	214 1.0×	25	902
Tomoki Yamano Japan	18	540 0.7×	364 0.5×	289 0.7×	74 0.3×	126 0.6×	54	972
Catalin Mihalcioiu Canada	14	422 0.5×	391 0.6×	155 0.4×	179 0.8×	156 0.7×	38	1000
Rebecca Ruhl United States	15	560 0.7×	328 0.5×	187 0.5×	211 0.9×	56 0.3×	23	967

Countries citing papers authored by Lerong Li

Since Specialization

Citations

This map shows the geographic impact of Lerong Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lerong Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lerong Li more than expected).

Fields of papers citing papers by Lerong Li

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lerong Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lerong Li. The network helps show where Lerong Li may publish in the future.

Co-authorship network of co-authors of Lerong Li

This figure shows the co-authorship network connecting the top 25 collaborators of Lerong Li. A scholar is included among the top collaborators of Lerong Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lerong Li. Lerong Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Li, Lerong, et al.. (2025). Cyclical Inequality in the Cost of Living and Implications for Monetary Policy. IMF Working Paper. 2025(264). 1–1.

Koeberl, Dwight D., Andreas Schulze, Neal Sondheimer, et al.. (2024). Interim analyses of a first-in-human phase 1/2 mRNA trial for propionic acidaemia. Nature. 628(8009). 872–877. 55 indexed citations breakdown →

Li, Lerong. (2022). Trade Policy Shocks and Consumer Prices. SSRN Electronic Journal. 2 indexed citations

Gudikote, Jayanthi, Tina Cascone, Alissa Poteete, et al.. (2021). Inhibition of nonsense-mediated decay rescues p53β/γ isoform expression and activates the p53 pathway in MDM2-overexpressing and select p53-mutant cancers. Journal of Biological Chemistry. 297(5). 101163–101163. 26 indexed citations

Lam, Vincent K., Jianjun Zhang, Carol C. Wu, et al.. (2020). Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLC. Journal of Thoracic Oncology. 16(4). 601–609. 58 indexed citations

Sen, Triparna, B. Leticia Rodriguez, Limo Chen, et al.. (2019). Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer. Cancer Discovery. 9(5). 646–661. 616 indexed citations breakdown →

William, William Nassib, Won‐Chul Lee, J. Jack Lee, et al.. (2019). Genomic and transcriptomic landscape of oral pre-cancers (OPCs) and risk of oral cancer (OC).. Journal of Clinical Oncology. 37(15_suppl). 6009–6009. 11 indexed citations

Meraz, Ismail M., Mourad Majidi, Xiaobo Cao, et al.. (2018). TUSC2 Immunogene Therapy Synergizes with Anti–PD-1 through Enhanced Proliferation and Infiltration of Natural Killer Cells in Syngeneic Kras -Mutant Mouse Lung Cancer Models. Cancer Immunology Research. 6(2). 163–177. 42 indexed citations

Gomez, Daniel R., Lauren A. Byers, Monique B. Nilsson, et al.. (2018). Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer. Oncotarget. 9(18). 14268–14284. 12 indexed citations

10.

Gay, Carl M., Pan Tong, Lerong Li, et al.. (2018). Abstract 2822: ATR inhibitors are active as single agents and in combination with PARP1 and ATM inhibitors in molecularly distinct subsets of small cell lung cancer models. Cancer Research. 78(13_Supplement). 2822–2822. 3 indexed citations

11.

Cascone, Tina, Haïfa Hamdi, Fahao Zhang, et al.. (2018). Abstract 1719: Superior efficacy of neoadjuvant compared to adjuvant immune checkpoint blockade in non-small cell lung cancer. Cancer Research. 78(13_Supplement). 1719–1719. 33 indexed citations

12.

Sen, Triparna, Pan Tong, Lixia Diao, et al.. (2017). Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer. Clinical Cancer Research. 23(20). 6239–6253. 101 indexed citations

13.

Zhang, Ming, Ratnakar Singh, Shaohua Peng, et al.. (2017). Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors. Cancer Letters. 392. 71–82. 23 indexed citations

14.

Valenzuela, Nicolas, Benjamin Soibam, Lerong Li, et al.. (2017). HIRA deficiency in muscle fibers causes hypertrophy and susceptibility to oxidative stress. Journal of Cell Science. 130(15). 2551–2563. 11 indexed citations

15.

Sen, Triparna, Pan Tong, C. Allison Stewart, et al.. (2017). CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib. Cancer Research. 77(14). 3870–3884. 145 indexed citations

16.

Kalu, Nene N., Tuhina Mazumdar, Shaohua Peng, et al.. (2017). Genomic characterization of human papillomavirus-positive and -negative human squamous cell cancer cell lines. Oncotarget. 8(49). 86369–86383. 43 indexed citations

17.

Cardnell, Robert J., Lerong Li, Triparna Sen, et al.. (2017). Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies. Oncotarget. 8(43). 73419–73432. 61 indexed citations

18.

Zheng, Yan, Uta Ceglarek, Tao Huang, et al.. (2016). Weight-loss diets and 2-y changes in circulating amino acids in 2 randomized intervention trials. American Journal of Clinical Nutrition. 103(2). 505–511. 67 indexed citations

19.

Wang, Yuehong, Ratnakar Singh, Liguang Wang, et al.. (2016). Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations. Oncotarget. 7(30). 47998–48010. 18 indexed citations

20.

Ferrarotto, Renata, Suk Young Yoo, Pan Tong, et al.. (2015). Epithelial–Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor–Mediated Apoptosis in Non–Small Cell Lung Cancer. Clinical Cancer Research. 22(7). 1674–1686. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact